A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Inclusion Criteria
Exclusion Criteria
Chapel Hill, North Carolina 27599-7080, United States
Oklahoma City, Oklahoma 73118, United States
SAN M. de Tucuman, T4000AXL, Argentina
Nanjing, 210000, China
Taian, 271000, China
Wenzhou, 315100, China
Saint-Priest-en-Jarez, 42270, France
Vandœuvre-lès-Nancy, 54511, France
Hamburg, 20251, Germany
Chiyoda-ku, 101-8643, Japan
Chuo-ku, Sapporo-shi, 060-0033, Japan
Higashiibaraki, 311-3117, Japan
Kitakyusyu-shi, 802-0077, Japan
Kumagaya-shi, 360-8567, Japan
Kurume-shi, 839 0809, Japan
Osaka, 540-0006, Japan
Shinjyuku-ku, 162-8655, Japan
Lembah Pantai, 59100, Malaysia
Culiacán, 80230, Mexico
Saint Petersburg, 197110, Russia
Vranov N. Toplou, 093 01, Slovakia
Haeundae-gu, 48108, South Korea
Las Palmas de GC, 35019, Spain
Ivano-Frankivsk, 76008, Ukraine
Kyiv, 04106, Ukraine
Kyiv, 4078, Ukraine
Lviv, 79000, Ukraine
Lviv, 79010, Ukraine
Odesa, 65025, Ukraine